FDA approves first cholesterol pill of its kind
Enlicitide, the new oral PCSK9 inhibitor from Merck, will be sold under the brand name Lipfendra. It is approved to reduce LDL-C in patients with hypercholesterolemia, including HeFH.
Enlicitide, the new oral PCSK9 inhibitor from Merck, will be sold under the brand name Lipfendra. It is approved to reduce LDL-C in patients with hypercholesterolemia, including HeFH.
What's Your Reaction?
:max_bytes(150000):strip_icc()/GettyImages-2187410260-5afe56694791404f99c253dd8d5abe6a.jpg?#)
